Work

P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC

Year: 2019

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2019.08.1317

Authors: S. Aix, S. Novello, E. Garon, K. Nakagawa, E. Nadal, D. Moro-Sibilot, M. Alonso Garcia, E. Fabre, B. Frimodt-Moller, A. Zimmermann, C. Visseren-Grul, M. Reck

Institutions: Hospital Universitario 12 De Octubre, University of Turin, University of California, Los Angeles, Kindai University, Institut Català d'Oncologia, Centre Hospitalier Universitaire de Grenoble, Hospital Universitario Virgen del Rocío, Hôpital Européen Georges-Pompidou, Eli Lilly (United States), Eli Lilly (Netherlands), German Center for Lung Research, LungenClinic Grosshansdorf

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2981507927

FWCI:

Cites:

Cited by:

Related to: 10